Sarepta Therapeutics

Phase A — Understand the business

Lens 1 · Company Overview

What it is. Sarepta Therapeutics (Nasdaq: SRPT; Cambridge, MA; incorporated Oregon 1980, reincorporated Delaware 2013) is a commercial-stage biopharmaceutical company focused on rare neuromuscular disease, principally Duchenne muscular dystrophy (DMD), built on three modalities: phosphorodiamidate morpholino oligomers (PMO / exon-skipping), AAV gene therapy, and — newly — siRNA knockdown. As of Dec 31 2025 it had 835 employees (71% in R&D), down sharply after a mid-2025 restructuring.

How it makes money — four approved products:

• PMO / exon-skipping ("PMO Products"): EXONDYS 51 (eteplirsen, exon 51), VYONDYS 53 (golodirsen, exon 53), AMONDYS 45 (casimersen, exon 45) — the legacy cash engine. FY2025 PMO product revenue $965.6M (flat YoY: −$1.6M).
• Gene therapy: ELEVIDYS (delandistrogene moxeparvovec / SRP-9001), the first DMD gene therapy, accelerated approval June 2023, label expansion June 2024. FY2025 ELEVIDYS revenue $898.7M (+9% YoY, but see the crisis below).

FY2025 revenue mix:

• Products, net: $1,864.3M (+4% YoY)
• Collaboration and other: $333.9M (+193% YoY — Roche + Arrowhead)
• Total revenue: $2,198.2M (+16% YoY)

Customers & channel. Sarepta sells through specialty distributors/customers who resell to sites of care, or direct to sites of care; revenue is booked net of heavy variable consideration (Medicaid/PHS rebates, chargebacks, distribution fees). The customer base is concentrated (typical of ultra-rare-disease specialty distribution) but the 10-K does not break out named-customer concentration percentages in the extracted sections — n/a at the named-customer level.

Key partners / payment terms.

• Roche (F. Hoffmann-La Roche): ex-US license/collaboration for ELEVIDYS since Dec 2019 (closed Feb 2020), 14 amendments. Roche commercializes ELEVIDYS outside the US; Sarepta retains all US rights and manufactures/supplies globally. This is the backbone of "collaboration revenue".
• Arrowhead Pharmaceuticals: Nov/Dec 2024 global siRNA license — $500M cash upfront + $325M equity + $50M/yr for 5 years + up to ~$10B milestones for 7 siRNA programs incl. SRP-1001 (FSHD), SRP-1003 (DM1). This is the explicit future-pipeline bet.

Why this matters: The business is two companies bolted together — a still-cash-generative legacy exon-skipping franchise, and a gene-therapy/siRNA growth story where the gene-therapy half just blew up. The reported P&L (a Q1-2026 profit) is flattered by lumpy collaboration milestones; the operating business is shrinking.

Lens 2 · Supply Chain

Map: plasmid/raw materials → CDMO viral-vector & PMO manufacturing → Sarepta → specialty distributor → site of care → patient. Named stakeholders:

• Aldevron LLC — GMP-grade plasmid DNA for gene-therapy programs; reserved capacity / advance payments; agreement extended to Dec 31 2028 (Jan 2025 amendment).
• Catalent, Inc. — primary gene-therapy (ELEVIDYS) commercial CDMO; leases embedded in the supply agreement (ROU assets on balance sheet); an August 2025 "Letter Agreement" was signed specifically to address financial/operational fallout of the ELEVIDYS Suspension. Chokepoint: ELEVIDYS commercial supply is concentrated with Catalent.
• Thermo Fisher / Brammer Bio — former gene-therapy CDMO; agreement terminated (notice July 18 2024, effective Aug 21 2024); $55.4M R&D charge; Brammer filed an arbitration demand (Dec 2024) settled July 2025 for $13.0M.
• Euroapi Germany GmbH — PMO raw-material supplier; Oct 24 2025 side letter suspended/paused certain PMO raw-material manufacturing; Sarepta booked ~$25.5M of cost-of-sales charges (2025 + 2026 minimum commitments), and judged it not probable commercial supply resumes in 2026. A live signal that Sarepta is shrinking PMO manufacturing commitments.
• University of Western Australia (UWA) — exon-skipping IP license; low-single-digit royalty on net sales; ~$12.1M/yr royalty expense in cost of sales.

Chokepoints / single-source dependencies: (1) Catalent for ELEVIDYS viral-vector commercial supply; (2) Aldevron for plasmid; (3) the AAVrh74 capsid itself — see Lens 3/10, a scientific single point of failure, not just a supplier one. The supply chain is being actively down-sized (Thermo terminated, Euroapi paused) as demand falls — a chain in retreat, not expansion.

Lens 3 · Competitive Advantages (moats)

Real moats:

1. First-mover + installed base in DMD exon-skipping. Three approved PMO drugs (exons 51/53/45) covering the most common DMD-amenable mutations; a >$5B cumulative franchise. Switching costs are high — these are chronic therapies for an ultra-rare population with established payer coverage and patient-assistance infrastructure.
2. ELEVIDYS = the only approved DMD gene therapy (first and, as of mid-2026, still effectively the only commercial one) — a regulatory moat, now badly cracked (label cut to ambulatory).
3. IP estate — owned + UWA/BioMarin-licensed exon-skipping patents; Sarepta has won key patent fights (a $115.2M jury verdict against Nippon Shinyaku over Viltepso, Dec 2024).
4. Manufacturing/CMC know-how for PMO at scale.

Bargaining power: Strong over payers (ultra-rare, no alternatives) historically; weakening as (a) the safety overhang hands payers a reason to restrict, and (b) cleaner-safety gene-therapy rivals approach. Over suppliers, Sarepta is now the one cutting commitments (Euroapi/Thermo), implying it currently has the upper hand on volume — but only because its own demand is falling.

The moat problem: the gene-therapy moat was built on the AAVrh74 platform, and that platform is now the source of the liability — the FDA revoked the AAVrh74 platform technology designation (granted June 2 2025) after the deaths. A moat that turns into the murder weapon is not a moat. The durable moat is the PMO legacy franchise; the gene-therapy "moat" is contingent on regulatory rehabilitation.

Lens 4 · Segments

Sarepta reports as a single operating/reportable segment. Product- and geography-level detail:

By product (net product revenue, $K):

By geography (within PMO, $K):

The trend that matters is masked by the annual numbers. FY2025 ELEVIDYS looks +9%, but that is a full-year figure spanning a strong H1 and a collapsing H2 (the safety crisis hit mid-2025). The quarterly view (Lens 5) tells the truth: Q1-2026 ELEVIDYS revenue was only $102.0M, i.e. a ~$400M annualized run-rate vs ~$900M in FY2025 — a >50% step-down. PMO is a flat-to-declining annuity; ELEVIDYS is in free-fall; the only growth line is collaboration revenue, which is milestone-lumpy, not a franchise.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print: Q1-2026, ended Mar 31 2026)

Headline (10-Q):

• Products, net: $330.5M vs $611.5M Q1-2025 → −46% YoY (the single most important number in this dossier).
• Collaboration and other: $400.3M vs $133.3M → +200% (Arrowhead/Roche milestones).
• Total revenue: $730.8M vs $744.9M (−2%, held up only by collaboration).
• R&D: $154.0M vs $773.4M Q1-2025 (the prior-year quarter carried a huge Arrowhead up-front charge; the drop is mechanical, not efficiency).
• Operating income: +$358.4M vs −$300.4M.
• Net income: +$330.96M; EPS $3.15 basic / $2.88 diluted vs −$4.60.

Within the product line: of the $330.5M, ELEVIDYS was $102.0M and PMO was $228.6M — PMO is now 2.2x ELEVIDYS, a stunning reversal for a company that 18 months ago was a gene-therapy growth story.

Read it correctly: This is a GAAP profit that hides an operating deterioration. The $331M net income is essentially the Arrowhead/Roche collaboration revenue ($400M) minus a now-small cost base — a one-quarter milestone artifact. Strip collaboration revenue and the underlying product franchise is shrinking ~46% YoY with ELEVIDYS demand cut in half. Do not be fooled by the EPS.

FY2025 full year for context:

• Total revenue $2,198.2M; Net LOSS $(713.4)M; EPS $(7.13) vs FY2024 net income $235.2M / EPS $2.34 — a $948.6M swing.
• Drivers: cost of sales +163% to $839.6M (inventory write-downs / impairments tied to ELEVIDYS supply); R&D +89% to $1,522.1M (the $883.8M Arrowhead up-front/milestone charge ran through R&D); a $42.0M restructuring charge.

Balance-sheet flags (Dec 31 2025):

• Cash & equivalents $801.3M; total cash+investments+restricted $953.8M.
• Inventory $914.7M current + $184.5M non-current = $1,099.2M — very high relative to a falling revenue line; a write-down risk if ELEVIDYS demand stays impaired (see Lens 10).
• Accounts receivable fell to $398.2M (from $602.0M) — consistent with lower sales.
• Deferred revenue current jumped to $443.4M (from $130.3M) — collaboration cash received but not yet recognized (a positive liquidity tell).
• Long-term debt $829.0M (the 2027/2030 convertibles); undrawn $600M revolver.
• Management asserts liquidity is "sufficient to fund our current operational plan for at least the next twelve months" — i.e. no going-concern qualification, but the language is explicitly framed around meeting "2027 financial obligations".

Market reaction / guidance: FY analyst commentary noted Q4-2025 ELEVIDYS sales of ~$110M missed, prompting price-target trims. The stock sits ~$17 (June 2026), down ~85%+ from early-2025 levels.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the research-layer shelf (transcripts/ empty). From `` coverage of the FY2025/Q1-2026 cycle:

• Tone shift: management has moved from a 2023-24 gene-therapy-growth narrative to a 2025-26 survival-and-pivot narrative — "align cost structure," "meet 2027 financial obligations," "prioritize siRNA," "fully fund the pipeline".
• What they stopped saying: the AAVrh74 "platform technology" framing (the designation was revoked); non-ambulatory ELEVIDYS expansion (removed from the label).
• What they now emphasize: the Arrowhead siRNA early data (Phase 1/2 readouts March 2026 showing high muscle concentrations / target engagement without severe side effects) — the bull's entire pivot rests here.
• Credibility overhang: the CEO and two named officers are defendants in a securities class action alleging they misrepresented ELEVIDYS safety (Lens 10), which colors every forward statement. ``-labeled; treat call sentiment as summary-derived (no primary transcript).

Lens 7 · Comps

Peer set: rare-disease / genetic-medicine names (genomics/+clinical cohort).

Read: Sarepta now trades like a distressed/declining rare-disease name (~0.8x P/S), not a growth biotech. The startling comp is that Sarepta ($1.8B) is roughly the size of clinical-stage Ultragenyx ($2.3B) and a fraction of pre-/early-commercial Krystal ($9B) and BioMarin ($10B) — despite Sarepta having ~$1.9B of actual product revenue. The market is pricing Sarepta's revenue base as a melting ice cube. Either it is cheap (the legacy PMO annuity + optionality on siRNA is worth more than $1.8B) or the market is right that ELEVIDYS keeps bleeding and siRNA is years away. That is the whole debate.

Lens 8 · Stock-Price Catalysts (>5% moves, last ~5y)

``-sourced timeline:

• June 2023 — ELEVIDYS accelerated approval (first DMD gene therapy): major positive re-rate; franchise narrative born.
• June 2024 — ELEVIDYS label expansion to age 4+: positive.
• ~March 2025 — first ELEVIDYS-linked patient death disclosed: stock −22% in a day (to ~$78.54 from ~$101.35).
• Mid-2025 — second death + FDA clinical hold on LGMD trials + AAVrh74 platform designation revoked + 36% layoff (July 16 2025): stock down 85% YTD by Aug 2025 ($11.6B → ~$1.75B mkt cap).
• ~Mid-2025 — third death (in the SRP-9004/LGMD trial, same AAVrh74 vector) → FDA-requested shipment pause, then resumed for ambulatory only ~10 days later.
• Nov 3 2025 — ESSENCE confirmatory trial MISS (VYONDYS 53 / AMONDYS 45 primary endpoint not met) — threatens the legacy PMO franchise's full-approval conversion.
• Nov 2025 — boxed warning for acute liver injury/failure added; non-ambulatory indication removed.
• Feb 25-26 2026 — CEO Doug Ingram announces retirement by end-2026.
• March 2026 — positive Arrowhead siRNA Phase 1/2 data: a rare green shoot.
• Q4-2025 / Q1-2026 prints — ELEVIDYS revenue misses (~$110M Q4, $102M Q1): target trims.

What the market actually reacts to for this name: patient safety / FDA actions on the gene-therapy franchise — by a mile. Earnings matter at the margin; deaths and label changes are the price drivers. Secondary: clinical readouts (ESSENCE down, Arrowhead up). This is a headline-risk, binary-event stock, not a fundamentals-grind stock.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO Douglas Ingram (since 2017; ex-President of Allergan, ~2 decades there). Track record: pushed three DMD therapies to approval, built Sarepta into a ~$15B company at peak, generated >$5B from the exon-skipping class. Also presided over the ~85% collapse, the safety crisis, and is a named defendant in the securities class action. Announced retirement by end-2026 — citing the "shocking, ironic" diagnosis of his wife and son with DM1 (the very disease the Arrowhead deal targets). A leadership vacuum at the worst possible moment; succession unresolved.
• Louise Rodino-Klapac — President of R&D & Technical Operations; the scientific architect of the gene-therapy platform; also a named defendant in the securities suit.
• Ian Estepan — President & COO (added as a defendant in the amended complaint).
• Capital-allocation history: Mixed-to-poor on the big swings. The Arrowhead deal ($500M cash + $325M equity + up to $10B milestones) was struck Nov 2024, before the gene-therapy crisis fully broke — arguably prescient diversification, arguably overpaying at the top. The 2022 $1.15B convertible raise funded the gene-therapy build that is now impaired. FY2025 ROE is negative (net loss $713M). The 2025 debt exchanges traded a 1.25% coupon for 4.875% (2030 notes) to push out maturities — survival financing at a high price (Lens 11).
• Red flags: named in securities + 3 derivative suits; a $140.5M Q3-2025 restatement of a debt-extinguishment loss (error correction) — a controls smell, though disclosed and corrected.
• Archetype: professional manager (Ingram is a lawyer/operator, not a scientist-founder). For a company that now needs a credible safety/regulatory-rehabilitation story AND a clean pivot to a new modality, the incoming CEO choice is itself a catalyst.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst. Items, every figure labeled:

1. Inventory vs. falling revenue (highest-priority flag). $914.7M current + $184.5M non-current inventory at Dec 31 2025 against an ELEVIDYS line now running ~$102M/qtr. Cost of sales already +163% in FY2025 (included a $17.0M ELEVIDYS prepaid-deposit impairment). If ELEVIDYS demand stays at the impaired run-rate, further inventory write-downs are likely — watch cost-of-sales and any "excess & obsolete" disclosures.
2. GAAP profit driven by collaboration revenue, not products. Q1-2026 net income $331M is essentially the $400M collaboration line; non-GAAP/quality-of-earnings is low — the recurring operating franchise is loss-making once milestones are stripped.
3. Revenue recognition / deferred revenue. Deferred revenue current spiked to $443.4M — collaboration cash recognized over time; timing of recognition will make GAAP earnings lumpy and potentially flattering in milestone quarters. Not a fraud flag, but an earnings-quality caution.
4. $140.5M restatement (Q3-2025). Debt-extinguishment loss was misstated and corrected in Q4-2025 — a real internal-controls yellow flag, though self-corrected and immaterial to cash.
5. $12.1B of contingent milestone obligations off-balance-sheet — not recorded (not probable), but a large contingent claim on future cash if siRNA programs advance.
6. Stock-based comp / dilution. Shares outstanding rose to ~105.6M (Dec 2025) from ~96.9M (Dec 2024); the debt exchanges issued ~5.85M + ~1.1M shares. Dilution is an active feature of the survival financing.
7. Valuation allowance. Full valuation allowance against deferred tax assets maintained — management's own signal it does not assume a return to sustained profitability.

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: None. Verified via SEC EDGAR EFTS (LR + AAER) search, 2021-06-29 → 2026-06-29 — total_sec_findings: 0.
• Non-SEC enforcement (web search): The dominant regulatory event is FDA action on ELEVIDYS — boxed warning for acute liver injury/failure, removal of the non-ambulatory indication, a shipment pause then ambulatory-only resumption, a clinical hold on LGMD gene-therapy trials, and revocation of the AAVrh74 platform technology designation. These are safety/labeling actions, not fraud penalties — but they are the entire investment risk. No FTC/DOJ monetary penalty found.
• 10-K Item 3 / Note 23 (Legal Proceedings) — company's own disclosure:
• Securities class action (filed June 26 2025, S.D.N.Y. → transferred to D. Mass.; amended Jan 22 2026): alleges Exchange Act §10(b)/Rule 10b-5 violations re ELEVIDYS safety/efficacy disclosures, LGMD/AAVrh74 safety, and the ESSENCE trial; class period June 22 2023 – Nov 3 2025; defendants include CEO Ingram, COO Estepan, R&D President Rodino-Klapac. Motion to dismiss due March 9 2026.
• Three shareholder derivative actions (consolidated, stayed pending the securities action) — name the board + officers; allege breaches of fiduciary duty + §14(a).
• Regenxbio/U-Penn patent suits: '617 patent — district court invalidated it (Jan 2024), but the Federal Circuit REVERSED and remanded on Feb 20 2026 (a re-opened infringement risk on AAV manufacturing); '274 patent IPR/appeal pending.
• Genzyme patent suit (ELEVIDYS) — trial set June 14 2027.
• Nippon Shinyaku — Sarepta won ~$115.2M jury verdict (Dec 2024) for Viltepso infringement (a positive).
• Brammer/Thermo arbitration — settled $13.0M (July 2025).
• Conclusion: No accounting-fraud enforcement, but a material securities class action squarely on the safety-disclosure question, a re-opened patent threat (Regenxbio '617), and an FY2027 Genzyme trial. The legal overhang is real and tied directly to the thesis.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection — EPS, rNPV, and the runway-to-catalyst question

This is +clinical-overlaid, so the EPS line is low-information (GAAP earnings are milestone-driven) and the questions that matter are (a) does cash reach the next siRNA value-inflection, and (b) what is the lead-asset rNPV. EPS path is provided for completeness but flagged as unreliable.

EPS sketch (FY2026–FY2028), every input labeled, output ``:

• FY2026 base: Product revenue ~$1.3–1.5B ; collaboration revenue **highly variable** (could be $0.5–1.5B depending on Arrowhead/Roche milestone timing). Because collaboration swings dominate, **FY2026 GAAP EPS could plausibly print anywhere from a modest loss to ~$3–5 positive** purely on milestone timing — i.e. not a usable signal. n/a — not meaningfully forecastable is the honest answer for a committed base-case EPS.
• FY2027–28: Hinge entirely on (i) whether ELEVIDYS stabilizes in ambulatory-only (~$400M floor?) or keeps bleeding, (ii) the ESSENCE/PMO full-approval outcome, (iii) siRNA milestone cadence. Too many binaries for a credible point estimate.

rNPV — lead-asset framing (``, illustrative, inputs labeled):

• PMO franchise (closest to an annuity): ~$0.9B revenue, but ESSENCE miss threatens accelerated-approval conversion; if it survives, a mid-single-digit-multiple-of-earnings annuity. The clearest source of value today.
• ELEVIDYS (ambulatory-only): peak US sales maybe ~$0.4–0.6B `` if it stabilizes, × ongoing safety-discount; ex-US is Roche's economics (royalty/milestone to Sarepta).
• Arrowhead siRNA (SRP-1001 FSHD, SRP-1003 DM1, +5): the re-rate optionality. Early Phase 1/2 positive, but commercial revenue is 2027-2029, and Sarepta owes Arrowhead up to ~$10B in milestones + $50M/yr. rNPV is real but deeply PoS-discounted and back-ended. n/a — peak-sales not yet sourceable for a hard number.

Runway-to-catalyst (the lens that actually matters): Cash + investments $953.8M (Dec 2025); undrawn $600M revolver; management says ≥12 months of runway and the debt exchanges pushed $893.4M of principal from 2027 to 2030. Verdict: the company has bought time — runway likely reaches the next siRNA data inflections, provided product cash doesn't deteriorate faster than modeled and collaboration milestones keep landing. The 4.875% 2030 notes and the ~$158.6M residual 2027 notes are the watch items.

Brier forecast: Not logged — per --watchlist rules (no forecast.ts create in the breadth loop, and the wave boundary forbids it). The natural binary to track if promoted: "ELEVIDYS US net product revenue returns to >$150M in any quarter of FY2026" (p ≈ 0.30, ``) — a clean test of whether the franchise stabilizes or melts.

Lens 12 · Bull vs Bear

Bull case. Sarepta at ~$1.8B is a broken growth stock priced as a melting annuity, with free optionality on a de-risked new modality. (1) The PMO franchise (~$0.9B, cash-generative) alone arguably supports much of the market cap. (2) ELEVIDYS survives in ambulatory patients — the FDA reinstated ambulatory shipments within ~10 days, signaling it sees a viable benefit/risk there; a ~$400M+ floor franchise plus Roche ex-US economics. (3) The Arrowhead siRNA pipeline (7 programs, FSHD/DM1 large markets vs ultra-rare DMD) showed positive Phase 1/2 data (March 2026) with no severe safety signal — if it reads out, Sarepta re-rates on a clean, larger-market modality, exactly when sentiment is washed out. (4) Liquidity de-risked — maturities pushed to 2030, ≥12-month runway. (5) A new CEO + settled litigation could remove two overhangs at once. Contrarian read: the market is extrapolating "biotech with dead patients = zero" onto a company that still does ~$1.9B of revenue and just bought a second act.

Bear case (permanent-impairment risks). (1) The AAVrh74 platform is structurally compromised — three deaths, same vector, designation revoked; all of Sarepta's gene-therapy value (ELEVIDYS non-ambulatory + LGMD SRP-9003/9004) is impaired, and a fourth death anywhere on this vector could pull ELEVIDYS entirely. (2) ELEVIDYS demand has halved and may keep falling — physicians and families have a safety reason to wait for cleaner rivals. (3) Competitors are explicitly weaponizing safety — Solid Biosciences (SGT-003) reported higher microdystrophin expression than ELEVIDYS with no liver injury; Regenxbio (RGX-202) well-tolerated with functional improvement. Pfizer exited DMD, but the next-gen AAV entrants are the real threat — they take the gene-therapy market with a cleaner label. (4) ESSENCE miss threatens PMO full-approval conversion → the "safe" annuity is not fully safe. (5) Securities class action + Regenxbio '617 reversal + Genzyme 2027 trial = legal tail. Pre-mortem (18 months out, thesis broke): a fourth AAVrh74 safety event forces full ELEVIDYS withdrawal; a cleaner rival gets approved; ESSENCE leads FDA to pull/relabel a PMO drug; siRNA data slips; cash burn forces a dilutive raise at a distressed price — equity halves again. Multiples: ~0.8x P/S is not obviously cheap if revenue is in secular decline and the siRNA assets are years and billions-of-milestones away.

Contrarian view (what the market refuses to see): Both tails are underpriced. Bears treat it as terminal; bulls treat the siRNA pivot as a sure thing. The truth is it's a genuine binary — and the asymmetry only works if (a) you size it small and (b) the catalyst you're underwriting is siRNA data, not ELEVIDYS recovery. ELEVIDYS is a value trap; siRNA is the option. Buying SRPT for ELEVIDYS is the mistake; buying a sliver for Arrowhead-siRNA optionality at a washed-out price is the trade.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• What structurally breaks the money machine: the same viral vector underlies the entire gene-therapy franchise; safety is not a fixable "manufacturing" problem, it's mechanism (immune response to AAV → liver failure). You cannot engineer your way out of your own platform in the installed product.
• Revenue concentration: ELEVIDYS + PMO are all DMD/neuromuscular; there is no diversification cushion until siRNA commercializes (years away). One disease, one vector, one safety story.
• Why the moat is weaker than bulls think: the "first/only gene therapy" moat is precisely what's killing patients; rivals are entering with the explicit pitch "no liver injury." First-mover in a modality that maims is a liability, not a moat.
• Most dangerous competitor bulls underestimate: Solid Biosciences (SGT-003) — higher expression, clean safety so far; and Regenxbio (RGX-202) near FDA submission. Either approval re-frames ELEVIDYS as the dangerous old option.
• Worst capital allocation: paying ~$825M cash+equity (plus up to $10B milestones) to Arrowhead at the top, funded by a balance sheet that then needed survival debt exchanges at 4.875%; plus a $140.5M restatement.
• Assumptions that must hold for today's price: ELEVIDYS doesn't get fully pulled; PMO survives ESSENCE; siRNA reads out and commercializes on time; no dilutive raise; the class action settles cheaply. That's five things that all have to go right.
• If growth disappoints 20-30%: product revenue toward ~$1.0-1.1B with collaboration lumpiness → the equity is a coin-flip on milestones; ~0.8x P/S can become ~0.8x of a smaller number.
• Single scenario that permanently impairs: a fourth AAVrh74 death → full ELEVIDYS withdrawal + LGMD programs dead + class action damages balloon. Plausibility: non-trivial given three deaths already on the same vector. This is the short thesis in one line.

Lens 14 · Management Questions (15, ordered by information value)

1. With three deaths now tied to the AAVrh74 vector, what is your specific, mechanistic plan to de-risk immune/liver toxicity in the existing ambulatory ELEVIDYS population — and what would trigger you to voluntarily withdraw it?
2. What is the current weekly/monthly ELEVIDYS prescription run-rate, and what is the realistic stabilized floor for ambulatory-only US revenue?
3. After the ESSENCE miss, what is the FDA pathway for VYONDYS 53 / AMONDYS 45 full-approval conversion, and what is the probability they are pulled or relabeled?
4. Walk through the siRNA (Arrowhead) catalyst calendar program-by-program: next readouts, dates, and the single data point that most de-risks the FSHD and DM1 programs.
5. Given ~$1.1B of inventory against a halved ELEVIDYS run-rate, what write-downs should we model, and over what horizon?
6. What is the exact cash runway under a bear case (ELEVIDYS −30% from here, no new milestones), and at what point would you raise equity — and at what price discipline?
7. How do you respond, commercially, to Solid (SGT-003) and Regenxbio (RGX-202) marketing "no liver injury" directly against ELEVIDYS?
8. What are the terms and triggers of the Arrowhead milestone schedule (up to ~$10B) — how much is due in 2026-2028, and how is it funded?
9. On the CEO transition: what is the timeline, and what profile (commercial, scientific, turnaround) is the board prioritizing, and why?
10. What is your settlement strategy and reserve thinking on the securities class action and the consolidated derivative suits?
11. Post-Federal-Circuit reversal on Regenxbio's '617 patent, what is the manufacturing-infringement exposure and any royalty/redesign contingency?
12. Why was the Arrowhead deal the right use of ~$825M cash+equity in late 2024, in hindsight, versus preserving balance-sheet flexibility?
13. What is the plan for the 4.875% 2030 notes and residual 2027 notes — refinance, convert, or repay, and under what equity-price assumptions?
14. Which supply commitments (Catalent, Aldevron) are take-or-pay, and what is the downside cost if gene-therapy volumes stay depressed?
15. If you had to pick one program as the company's 2028 value driver, which is it — and what would convince a skeptic it works and sells?

---